Dormant
NP · Neptune Insurance Holdings Inc.
Last analysed ·
Against its published line
Nothing is through its line on this close.
How to read this
The red mark is the published kill line — the price that would prove the pick wrong. The dot is where the name closed on 14 August 2026; a dot LEFT of the mark has closed through its line.
Distance is drawn on a square-root scale, so close calls get the room. Past 8% a row stops competing and reads well clear, with a hollow dot to say the figure is off the drawn scale. Rows run tightest first.
Resolved Graded and closed 2026-08-28 at low conviction — the published kill line did not fire. Coverage continued after the close; the read below is dated 2026-09-20 and is not part of the scored record.
Current thesis
The 2026-07-21 beat-and-raise has round-tripped: the 2026-08-14 weekly close of $31.71 is under the $32 post-print shelf, BMO cut to Market Perform on 2026-07-30, and the CFO sold 100,000 shares into $30.74–$32.12 on Aug 12–13. Operations still compound (+33% Q2 revenue), but the fresh-attention leg is spent and nothing is dated before the ~late-October Q3 print.
Kill line
A weekly close below $30 loses the $30.74–$32.12 band held through mid-August and puts the 2026-05-13 follow-on price of $27.50 back in play; secondarily, a Q3 report (~2026-10-21, est.) that leaves the FY2026 $199M guide unraised, or no weekly close back above $32 before it, confirms the re-rating has stalled.
Pick status
Played out resolved published kill line did not fire How this is scored →Latest analysis and events for NP —
As of 20 September 2026, the latest FrontierPicks analysis for Neptune Insurance Holdings Inc. (NP): The 2026-07-21 beat-and-raise has round-tripped: the 2026-08-14 weekly close of $31.71 is under the $32 post-print shelf, BMO cut to Market Perform on 2026-07-30, and the CFO sold 100,000 shares into $30.74–$32.12 on Aug 12–13. Operations still compound (+33% Q2 revenue), but the fresh-attention leg is spent and nothing is dated before the ~late-October Q3 print.
Kill line: A weekly close below $30 loses the $30.74–$32.12 band held through mid-August and puts the 2026-05-13 follow-on price of $27.50 back in play; secondarily, a Q3 report (~2026-10-21, est.) that leaves the FY2026 $199M guide unraised, or no weekly close back above $32 before it, confirms the re-rating has stalled.
Current Thesis
Neptune Insurance’s private-flood growth story has failed its published price test: the 2026-09-18 close breached $30, and a renewed re-rating would require recovery of the $32 post-results shelf alongside stronger revenue guidance. The September 18 weekly close was $29.79 in the adjusted market series, triggering the condition published in the September 6 dossier. The operating evidence remains positive: the company reported second-quarter revenue growth of 33% on 2026-07-21. Company results
For the previously published re-rating leg, the narrative is dead — the 2026-09-18 weekly close broke its stated threshold. That is an inference about the market structure; the July operating results do not establish a business deterioration. The September 17 transcript headline is not evidence of a new reporting period: the company dated its second-quarter release July 21 and its conference call July 22. Company announcement
Bullish and bearish views on Neptune Insurance Holdings Inc.
The model's bull view on Neptune Insurance Holdings Inc. (NP), in brief: Growth remained measurable. On 2026-07-21, Neptune reported second-quarter revenue of $55.9 million, up 33%, and written premium of $126.9 million, up 31%. These are operating results supporting the private-flood expansion story. Company results Guidance established an operating… The bear view: The published threshold failed. The 2026-09-18 adjusted close of $29.79 was below both the September 6 dossier’s $30 invalidation threshold and its $32 post-results shelf. The earlier description of cooling without a break no longer fits those observations. Insider supply… Both cases follow in full.
Bull Case
- Growth remained measurable. On 2026-07-21, Neptune reported second-quarter revenue of $55.9 million, up 33%, and written premium of $126.9 million, up 31%. These are operating results supporting the private-flood expansion story. Company results
- Guidance established an operating test. Management’s 2026-07-21 presentation forecast full-year revenue of $199 million. A subsequent reduction would invalidate the operating-growth case independently of the price breach. Earnings presentation
Bear Case
- The published threshold failed. The 2026-09-18 adjusted close of $29.79 was below both the September 6 dossier’s $30 invalidation threshold and its $32 post-results shelf. The earlier description of cooling without a break no longer fits those observations.
- Insider supply continued in September. InsiderTrades reported on 2026-09-16 that director Jonathan Carlon sold 50,000 company shares on September 14. This documents another insider transaction; it does not establish the seller’s motive or explain the subsequent market decline. September transaction report
Setup & Price Structure
The 2026-09-18 adjusted reference close was $29.79, with the shares 15.2% below the supplied 52-week high of $35.11 and up 3.7% over three months. The 14-period relative strength index was 18.1. That reading measures recent price momentum; the supplied observations are insufficient to establish a reversal probability.
The $30 threshold remains the historical thesis-break condition. Lowering it after the September 18 breach would change the published test. Moving-average readings, trading-volume participation and retail-flow measurements are unavailable, so neither crowding nor capitulation is established by this evidence.
Catalyst Calendar (next 30 days)
No confirmed company reporting date was established for 2026-09-20 through 2026-10-20. The previously published October earnings estimate remains unconfirmed.
- 2026-09-30 — Atlas+ quarter-end checkpoint. The July 21 presentation placed the next Atlas+ phase in the third quarter. September 30 marks the end of that delivery window, not an announced launch or earnings date. A disclosed delay would contradict that timetable; delivery alone would not establish incremental revenue. Management’s product timetable
What Would Change Our Mind
The loss of the published price structure has already occurred: a weekly close below $30 was recorded at $29.79 on 2026-09-18. A weekly close above the previously identified $32 shelf would establish a price recovery, without reversing the historical invalidation.
A subsequent revenue forecast above management’s July 21 full-year figure of $199 million would strengthen a separate recovery case. An unchanged forecast would provide no additional guidance upgrade; a reduction would weaken the operating argument. July guidance
Correlation Notes
This remains a single-company setup; no comparative return series establishes a group correlation. Management stated on 2026-07-21 that Neptune does not take insurance risk onto its balance sheet. It also identified weak storm activity as a demand headwind. The relevant weather channels are therefore policy demand and carrier capacity; a quiet season alone does not establish higher Neptune earnings. Company explanation of the business model
Notes
- Neptune is a private-flood managing general agent (parent of Neptune Flood); screens filing it under managed care or health services are miscategorising the business.
- Atlantic hurricane season runs June to November with a statistical peak near September 10; a landfall is an unscheduled, two-sided event on any trading day in that window.
- Sponsor entities FTV and BSIV Hold 101 LP remain large registered Class A holders and have sold multi-million-share blocks; secondary supply is a standing feature of the float.
- The company guides and reports on adjusted EBITDA and adjusted EPS; GAAP results carried a net loss of -$24.37M on a TTM view through Q1 2026.
- A $100M buyback was authorized 2026-04-21 and repurchase pace is not disclosed intra-quarter, so the company bid is unobservable until the next filing.
- Reporting has landed about three weeks after quarter end (Q1 on 2026-04-22, Q2 on 2026-07-21), so the Q3 date can precede aggregator estimates.
Related · shared themes
OSCR
Oscar Health, Inc.
Oscar Health's higher earnings outlook and quantified 2027 pricing support a post-Investor-Day rerating. A weekly close above $32.76 before a weekly close below $29.83 would complete the price-confirmation test; the September 18, 2026 close of $32.13 leaves it unresolved.
CNC
Centene Corporation
Centene's margin-repair case requires sustained earnings guidance and a weekly close above $68.72 by its 2026-10-27 results. September's reaffirmation supports the earnings leg, but a weekly close below $65 or withdrawal or reduction of fiscal 2026 adjusted EPS guidance above $4.80 invalidates the case.
HNGE
Hinge Health, Inc.
Digital-MSK profitability re-rate broke out in May and was pushed into open price discovery by the 2026-06-09 mid-quarter raise (Q2 to $200–202M, +45%; FY26 to $818–824M). But nine sell-side target hikes in two weeks plus accelerating insider selling mark a late, distribution-prone phase, with no company catalyst until the ~2026-08-04 Q2 print.
HUM
Humana Inc.
Humana's Medicare Advantage margin-recovery story faces a renewed price test: an adjusted daily close above $409.80 before a daily close below $383. The September 1, 2026 earnings reaffirmation supports stability, while October Star Ratings test the quality-bonus premise.
See also · stocks to watch